AACR 2026 – Matisse pains a mixed picture for Innate
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
Innate shows Bicycle the path for Nectin-4
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
Corvus goes pivotal in peripheral T-cell lymphoma
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
